Bluebird declares the price of its gene therapy- Zynteglo
Bluebird Bio has set the price of its gene therapy Zynteglo at USD 1.8 million. Zynteglo, so far, has only been approved for treating rare blood disorders in the Europe Union. The full price of Zynteglo can be dispersed out for five years, at approximately USD 357,567 annually. The first gene therapy was the spinal muscular atrophy treatment Zolgensma, which was approved by the FDA last month. Its developer, Novartis, kept the price of the therapy at USD 2.1 million. These one-time therapies can have a life-long effect in treating diseases as compared to traditional medicines. But the huge upfront cost...
